The prognosis for<unk>  patients is not good which is worse than ALL and AML. Medical Blood Institute reported cases of CR rate was 31.6%, with a median remission are less than 6 months The median survival time is only 7.5 months. The life quality is also low because the immune function of patient is damaged seriously. They have to stay in hospital and need 24h care. In another study, the results showed that young age, normal karyotype and ALL induction therapy will have a better prognosis than Ph+, adult patients. The study shows median survival of children is 139 months versus 11 months of adults, 139 months for normal karyotype patients versus 8 months for ph+ patients.
Biphenotypic acute leukaemia
Aggressive NK-cell leukemia
Mixed-phenotype acute leukemia
Leukemoid reaction
Atypical chronic myeloid leukemia
Prolymphocytic leukemia
T-cell prolymphocytic leukemia
B-cell prolymphocytic leukemia